Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
Merck shared updates on the company’s oncology pipeline and focused R&D approach
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
The company intends to respond to the two minor observations within the stipulated time
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Subscribe To Our Newsletter & Stay Updated
